1733.Tw
1733.TW operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in the healthcare sector.
Business. 1733.TW operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in the healthcare sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
1733.TW operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to customers in the healthcare sector.
The company maintains a strong liquidity position, with a current ratio of 3.87, indicating that it has sufficient short-term assets to cover its short-term liabilities. Its liquidity FPT (free cash flow to total liabilities) is supported by a free cash flow of 84,765,000 TWD and total liabilities of 546,089,000 TWD, suggesting a healthy cash buffer. However, the company has a net cash position that is negative after subtracting total debt, which could pose a liquidity risk if cash flow were to decline.
In terms of profitability, the company's return on equity (ROE) is 8.71%, and its return on assets (ROA) is 6.74%, both of which are below the industry median for medical equipment and supplies firms. The company's price-to-earnings (P/E) ratio of 18.44 is in line with the industry average, but its price-to-book (P/B) ratio of 1.61 suggests that the market is valuing the company at a premium to its book value. The company's operating margin is 7.23%, and its net profit margin is 8.38%, which are both below the industry median, indicating that the company may be less efficient in converting revenue into profit.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to higher risk if demand in its primary market were to decline. The company's capital expenditures are relatively low, with a negative value of -19,259,000 TWD, suggesting that it is not investing heavily in new assets or expansion.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's revenue has remained relatively flat over the past few years, and there are no major drivers of growth or contraction currently in place. The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. However, the company's net cash position is negative after subtracting total debt, which could increase liquidity risk if cash flow were to decline.
Recent events, including filings and transcripts, have not revealed any major changes in the company's operations or strategy. The company has not issued any new shares or taken on significant debt in the recent past, and there are no major regulatory or legal issues currently affecting the company.
- The company has a strong liquidity position with a current ratio of 3.87, but its net cash position is negative after subtracting total debt.
- The company's profitability metrics, including ROE and ROA, are below the industry median, indicating potential inefficiencies in converting revenue into profit.
- The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which could increase risk.
- The company is expected to maintain a stable revenue trajectory with no significant growth or decline projected in the next fiscal year.
- The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 1733.TW Market data — financials · 2026-05-26